Brandt Simon D, Kavanagh Pierce V, Westphal Folker, Elliott Simon P, Wallach Jason, Stratford Alexander, Nichols David E, Halberstadt Adam L
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, D08W9RT, Ireland.
Drug Test Anal. 2017 Oct;9(10):1641-1649. doi: 10.1002/dta.2196. Epub 2017 May 10.
The psychoactive properties of lysergic acid diethylamide (LSD) have fascinated scientists across disciplines and the exploration of other analogues and derivatives has been motivated by deepening the understanding of ligand-receptor interactions at the molecular level as well as by the search for new therapeutics. Several LSD congeners have appeared on the new psychoactive substances (NPS) market in the form of blotters or powders. Examples include 1-propionyl-LSD (1P-LSD), AL-LAD, and LSZ. The absence of analytical data for novel compounds is a frequent challenge encountered in clinical and toxicological investigations. Two newly emerging lysergamides, namely N -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P-ETH-LAD, were characterized by gas chromatography-mass spectrometry (GC-MS), low and high mass accuracy electrospray MS(/MS), GC solid-state infrared analysis, high performance liquid chromatography diode array detection as well as nuclear magnetic resonance spectroscopy. Limited analytical data for ETH-LAD were previously available, whereas information about 1P-ETH-LAD has not previously been encountered in the scientific literature. This study extends the characterization of lysergamides distributed on the NPS market, which will help to make analytical data available to clinicians, toxicologists, and other stakeholders who are likely to encounter these substances. The analysis of a test incubation of 1P-ETH-LAD with human serum at 37°C by LC single quadrupole MS at various time points (0-6 h, once per hour and one measurement after 24 h) revealed the formation of ETH-LAD, suggesting that 1P-ETH-LAD might serve as a pro-drug. 1P-ETH-LAD was still detectable in serum after 24 h. Copyright © 2017 John Wiley & Sons, Ltd.
麦角酸二乙酰胺(LSD)的精神活性特性吸引了各个学科的科学家,对其他类似物和衍生物的探索不仅是为了加深对分子水平上配体 - 受体相互作用的理解,也是为了寻找新的治疗方法。几种LSD同系物已以吸墨纸或粉末的形式出现在新型精神活性物质(NPS)市场上。例子包括1 - 丙酰基 - LSD(1P - LSD)、AL - LAD和LSZ。新型化合物缺乏分析数据是临床和毒理学研究中经常遇到的挑战。两种新出现的麦角酰胺,即N - 乙基 - 6 - 去甲麦角酸二乙酰胺(ETH - LAD)和1P - ETH - LAD,通过气相色谱 - 质谱联用(GC - MS)、低分辨率和高分辨率电喷雾质谱(/ MS)、GC固态红外分析、高效液相色谱二极管阵列检测以及核磁共振光谱进行了表征。之前关于ETH - LAD的分析数据有限,而关于1P - ETH - LAD的信息在科学文献中尚未出现过。本研究扩展了在NPS市场上流通的麦角酰胺的表征,这将有助于为临床医生、毒理学家和其他可能接触到这些物质的利益相关者提供分析数据。通过液相色谱单四极杆质谱在不同时间点(0 - 6小时,每小时一次,24小时后一次测量)对1P - ETH - LAD与人类血清在37°C下进行的测试孵育分析显示,形成了ETH - LAD,这表明1P - ETH - LAD可能是一种前体药物。24小时后血清中仍可检测到1P - ETH - LAD。版权所有© 2017约翰威立父子有限公司。